Current Affairs Topics Quiz Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

What’s missing in the conversations about the HPV vaccine? Men

March 11, 2026 6 min read Science & Technology Social Issues GS Paper 2 (Health) GS Paper 3 (Science & Technology)
On This Page ▼

What Happened

  • The dominant public discourse around the Human Papillomavirus (HPV) vaccine in India frames it almost exclusively as a tool for preventing cervical cancer in women — overlooking that HPV causes significant cancer burden in men as well.
  • High-risk HPV strains are responsible for a substantial share of penile, anal, and oropharyngeal (throat/mouth) cancers in men — diseases that attract little awareness in India's HPV vaccination conversation.
  • As India expands its HPV vaccination programme under the Universal Immunisation Programme (UIP), medical experts are calling for the policy to be reoriented toward gender-neutral vaccination to achieve broader public health benefit.
  • India's indigenous HPV vaccine CERVAVAC, developed by the Serum Institute of India, is already approved for males aged 9–26 years, but public communication and government rollout have centred almost entirely on girls and cervical cancer prevention.

Static Topic Bridges

Human Papillomavirus (HPV) — Virology and Disease Burden

Human Papillomavirus is a group of more than 200 related viruses, of which over 40 types infect the genital and mucosal areas of both men and women. Infection is primarily through skin-to-skin or sexual contact and is extremely common — the WHO estimates that 1 in 3 men worldwide carries a genital HPV infection at any given time.

  • HPV types are classified as low-risk (types 6, 11 — causing genital warts) and high-risk or oncogenic (types 16, 18, 31, 33, 45, and 7 others — causing cancers).
  • High-risk HPV 16 and 18 together account for approximately 70% of all HPV-related cancers globally.
  • In women, persistent high-risk HPV infection causes virtually all cervical cancers; in India, HPV 16 and 18 are responsible for about 77% of cervical cancer cases.
  • In men, HPV causes: oropharyngeal cancer (throat, base of tongue, tonsils), penile cancer, and anal cancer. Over 90% of anal cancers and approximately 48–63% of penile cancers are HPV-attributable. India-specific data shows oropharyngeal carcinoma is the most prevalent HPV-related malignancy in males (63.2% of HPV-associated male cancers).
  • WHO classifies 12 HPV types as high-risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.

Connection to this news: The article's central argument rests on this virology — HPV is not a "women's disease." Because the virus causes cancer in multiple organ systems across both sexes, vaccination policy that targets only girls leaves a large pool of unprotected individuals and allows ongoing viral transmission.

CERVAVAC — India's Indigenous HPV Vaccine

CERVAVAC is India's first indigenously developed quadrivalent HPV vaccine, manufactured by the Serum Institute of India (SII). Its development was supported under the government's Mission COVID Suraksha and the Department of Biotechnology (DBT). It was formally launched by Prime Minister Narendra Modi in January 2024.

  • Type: Quadrivalent recombinant vaccine covering HPV types 6, 11, 16, and 18.
  • Approved for: Girls and women 9–26 years (cervical, vulvar, vaginal, anal cancer prevention) AND males 9–26 years (anal cancer, anal dysplastic lesions, genital warts).
  • Dosing schedule: 2 doses (at 0 and 6 months) for ages 9–14; 3 doses for ages 15–26.
  • Private market price: approximately ₹1,200–₹2,000 per dose; government procurement price substantially lower.
  • SII's achievement: making an HPV vaccine available at a fraction of the cost of imported alternatives (Gardasil, Cervarix), critical for India's scale of immunisation.
  • CERVAVAC is gender-neutral by approval — the policy gap is in how the government has communicated and deployed it.

Connection to this news: CERVAVAC's male approval is a factual anchor for the article's argument: there is no regulatory barrier to vaccinating boys — the gap is one of policy will and public communication. UPSC may test CERVAVAC's development context (Mission COVID Suraksha, DBT, Serum Institute) and its significance as an indigenously developed vaccine.

Universal Immunisation Programme (UIP) and HPV Vaccine Inclusion

The Universal Immunisation Programme is India's flagship child immunisation initiative, one of the largest in the world by coverage scope. It currently provides free vaccines against 12 vaccine-preventable diseases to children and pregnant women at government health facilities.

  • Currently covers: BCG, OPV, Hepatitis B, DPT, Hib, IPV, Measles-Rubella, JE (in endemic districts), Rotavirus, PCV, and Typhoid Conjugate Vaccine.
  • Process for addition: National Technical Advisory Group on Immunisation (NTAGI) reviews evidence → recommends to the Ministry of Health and Family Welfare → Ministry approves inclusion.
  • NTAGI recommended introducing quadrivalent HPV vaccine in UIP for girls aged 9–14 years (catch-up campaign for 14-year-olds, then routine at age 9).
  • The government launched a special HPV vaccination drive in 2024 targeting approximately 1.15 crore 14-year-old girls annually across States and UTs, with vaccine administered free at government facilities.
  • As of early 2026, UIP rollout covers girls only — inclusion of boys remains an ongoing policy debate, with health economists arguing for gender-neutral vaccination on cost-effectiveness grounds.

Connection to this news: The article critiques the narrowness of India's current UIP HPV vaccination framework. For UPSC GS2, the UIP and the process of vaccine inclusion (NTAGI's role) are recurring themes in health governance questions.

Gender Equity in Health Policy — The Case for Male HPV Vaccination

Gender equity in health is a cross-cutting GS1 and GS2 theme. The HPV vaccine debate is a textbook example of how gender assumptions embedded in health policy can leave both men and the overall disease prevention goal underserved.

  • The "cervical cancer only" framing excludes: (a) HPV-related cancers in men; (b) the role men play as a reservoir of HPV transmission; (c) the benefits of herd immunity achievable only with gender-neutral vaccination.
  • Vaccinating boys alongside girls reduces overall HPV prevalence in the population, protecting even unvaccinated individuals through herd immunity — a well-established epidemiological principle.
  • Countries such as Australia, the United States, and the UK have adopted gender-neutral HPV vaccination programmes — Australia achieved near-elimination of HPV 16/18 in young people within a decade.
  • UPSC Prelims may test this as a "which of the following is a misconception about HPV" type question — the correct answer being that men are also at significant risk and benefit from vaccination.
  • Expanding HPV vaccination to boys also has economic logic: oropharyngeal and anal cancers are expensive to treat and often detected at late stages in India due to low awareness.

Connection to this news: The article's core argument — that men are missing from the HPV vaccine conversation — maps directly onto this gender equity framework. For Mains, this supports answers on inclusive health policy, disease burden, and the limits of a gender-siloed approach to vaccination.

Key Facts & Data

  • HPV is the most common sexually transmitted infection globally; WHO estimates 1 in 3 men worldwide carry genital HPV at any given time.
  • High-risk HPV types: 12 classified by WHO, including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59.
  • HPV 16 and 18 together cause approximately 70% of HPV-attributable cancers globally.
  • In India, HPV 16 and 18 account for ~77% of cervical cancer cases.
  • Male HPV-related cancer burden in India: oropharyngeal carcinoma accounts for 63.2% of HPV-associated male cancers; penile cancers account for 1 in 4 HPV-associated cancers in India.
  • Over 90% of anal cancers are HPV-attributable; ~48–63% of penile cancers are HPV-attributable.
  • CERVAVAC: Quadrivalent (types 6, 11, 16, 18); approved for ages 9–26 in both males and females; developed by Serum Institute of India under Mission COVID Suraksha/DBT; launched January 2024 by PM Modi.
  • CERVAVAC price: ~₹200/dose to government; ₹1,200–₹2,000/dose in private market.
  • UIP HPV rollout target: ~1.15 crore 14-year-old girls annually (as of 2024 launch); boys not yet included.
  • NTAGI recommended 2-dose schedule for ages 9–14 (0 and 6 months); 3-dose for ages 15–26.
  • One woman dies of cervical cancer every 8 minutes in India — underscoring the magnitude of the disease burden that the current programme seeks to address.